MXPA03007358A - Transporters comprising spaced arginine moieties. - Google Patents

Transporters comprising spaced arginine moieties.

Info

Publication number
MXPA03007358A
MXPA03007358A MXPA03007358A MXPA03007358A MXPA03007358A MX PA03007358 A MXPA03007358 A MX PA03007358A MX PA03007358 A MXPA03007358 A MX PA03007358A MX PA03007358 A MXPA03007358 A MX PA03007358A MX PA03007358 A MXPA03007358 A MX PA03007358A
Authority
MX
Mexico
Prior art keywords
transport
transporters
moiety
subunit
arginine
Prior art date
Application number
MXPA03007358A
Other languages
Spanish (es)
Inventor
L Vandeusen Christopher
Original Assignee
Cellgate Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellgate Inc filed Critical Cellgate Inc
Publication of MXPA03007358A publication Critical patent/MXPA03007358A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)

Abstract

The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)nZ, (ZY)nZ, (ZYY)nZ and (ZYYY)nZ. Subunit "Z" is L-arginine or D-arginine, and subunit "Y" is an amino acid that does not comprise an amidino or guanidino moiety. Subscript "n" is an integer ranging from 2 to 10. The method for enhancing transport involves the administration of the aforementioned composition.
MXPA03007358A 2001-02-16 2002-02-14 Transporters comprising spaced arginine moieties. MXPA03007358A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26962701P 2001-02-16 2001-02-16
PCT/US2002/004491 WO2002065986A2 (en) 2001-02-16 2002-02-14 Transporters comprising spaced arginine moieties

Publications (1)

Publication Number Publication Date
MXPA03007358A true MXPA03007358A (en) 2004-12-13

Family

ID=23028023

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007358A MXPA03007358A (en) 2001-02-16 2002-02-14 Transporters comprising spaced arginine moieties.

Country Status (9)

Country Link
US (3) US7585834B2 (en)
EP (1) EP1401473B1 (en)
JP (1) JP2005508832A (en)
AT (1) ATE437647T1 (en)
AU (1) AU2002306500C1 (en)
CA (1) CA2437983C (en)
DE (1) DE60233137D1 (en)
MX (1) MXPA03007358A (en)
WO (1) WO2002065986A2 (en)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
EP1301213B1 (en) 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20050059031A1 (en) * 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
WO2002029410A2 (en) * 2000-10-06 2002-04-11 Quantum Dot Corporation Cells having a spectral signature, and methods of preparation and use thereof
WO2002065986A2 (en) * 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties
US7622446B2 (en) * 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
US7491702B2 (en) * 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
US6998113B1 (en) 2005-01-31 2006-02-14 Aquea Scientific Corporation Bodywashes containing additives
US7025952B1 (en) 2005-01-31 2006-04-11 Aquea Scientific Corporation Methods of preparation and use of bodywashes containing additives
US20060173709A1 (en) * 2005-01-31 2006-08-03 Traynor Daniel H Bodywash additive business methods
US7037513B1 (en) 2005-01-31 2006-05-02 Aquea Scientific Corporation Bodywash additives
US7169814B2 (en) * 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
DE60337040D1 (en) 2002-02-01 2011-06-16 Life Technologies Corp Oligonucleotide compositions with improved efficacy
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
WO2004063342A2 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
CN1761485B (en) * 2003-03-20 2010-04-28 日本化药株式会社 Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer
ATE479763T1 (en) * 2003-04-29 2010-09-15 Avi Biopharma Inc COMPOSITIONS FOR IMPROVING ANTISENSE EFFECTIVENESS AND TRANSPORT OF NUCLEIC ACID ANALOGUE INTO CELLS
KR101161823B1 (en) * 2003-05-01 2012-07-03 코넬 리서치 화운데이션,인크. Method and carrier complexes for delivering molecules to cells
US20050209147A1 (en) * 2004-01-16 2005-09-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of RhoA signaling
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
NZ593986A (en) * 2004-03-03 2013-07-26 Revance Therapeutics Inc Compositions comprising a protein and a carrier for topical diagnostic and therapeutic transport
ES2554821T3 (en) 2004-03-03 2015-12-23 Revance Therapeutics, Inc. Topical application and transdermal release of botulinum toxins
KR100578732B1 (en) * 2004-03-05 2006-05-12 학교법인 포항공과대학교 Inositol-based molecular transporters and processes for the preparation thereof
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
GB0413613D0 (en) * 2004-06-17 2004-07-21 Univ London Small molecule carriers
PL1792927T3 (en) * 2004-09-22 2013-09-30 Nippon Kayaku Kk Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US7001592B1 (en) * 2005-01-31 2006-02-21 Aquea Scientific Corporation Sunscreen compositions and methods of use
CA2599016A1 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
CN106039294A (en) 2005-03-03 2016-10-26 雷文斯治疗公司 Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20080112904A1 (en) * 2005-03-08 2008-05-15 Daniel Henry Traynor Sunscreen Compositions And Methods Of Use
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007038171A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
WO2007038172A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
WO2007038169A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Multi-valent guanidinium compounds for molecular translocation across cellular membranes and epithelial tissues
US8518414B2 (en) * 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
CA2638915A1 (en) * 2006-02-10 2007-08-23 The Regents Of The University Of California Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
US8653238B2 (en) * 2006-02-27 2014-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for transport of molecules with enhanced release properties across biological barriers
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2007111211A1 (en) 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
CA2652656A1 (en) 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
BRPI0714762A2 (en) 2006-09-27 2014-12-23 Paolo Botti DELIVERY INCREASE MEANS AND METHODS FOR BIOLOGICAL SYSTEMS
JP5548364B2 (en) * 2006-10-03 2014-07-16 日本化薬株式会社 Polymer conjugates of resorcinol derivatives
JP5503872B2 (en) 2006-11-06 2014-05-28 日本化薬株式会社 Polymer derivatives of nucleic acid antimetabolites
EP2090607B1 (en) * 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
MX2009007070A (en) * 2006-12-29 2009-07-10 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides.
BRPI0720730A2 (en) * 2006-12-29 2014-04-08 Revance Therapeutics Inc TOPICAL APPLICATION COMPOSITIONS AND METHODS AND TRANSDERMAL RELEASE OF BOTULINIC TOXINS STABILIZED WITH HIV-TAT-DERIVED POLYPEPTIDE FRAGMENTS.
CA2688812A1 (en) * 2007-05-21 2008-11-27 Aquea Scientific Corporation Highly charged microcapsules
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2008271050B2 (en) * 2007-06-29 2014-11-06 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
WO2009015385A1 (en) 2007-07-26 2009-01-29 Revance Therapeutics, Inc. Antimicrobial peptide, compositions , and methods of use
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
US7935816B2 (en) * 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
US20110160146A1 (en) * 2008-02-07 2011-06-30 National Institute of Health (NIH) Conjungation of Small Molecules to Octaarginine Transporters for Overcoming Multi-Drug Resistance
CN101977631A (en) * 2008-03-18 2011-02-16 日本化药株式会社 Polymer conjugate of physiologically active substance
JP5366940B2 (en) 2008-05-08 2013-12-11 日本化薬株式会社 Polymer conjugate of folic acid or folic acid derivative
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
ES2347119B2 (en) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela POLYARGININE NANOCAPSULES.
JP5544357B2 (en) 2009-05-15 2014-07-09 日本化薬株式会社 Polymer conjugate of a physiologically active substance having a hydroxyl group
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN102933702A (en) 2009-11-18 2013-02-13 小利兰·斯坦福大学托管委员会 Methods of inducing tissue regeneration
NO2504357T3 (en) * 2009-11-23 2017-12-30
EP2563380B1 (en) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (en) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2566496B1 (en) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
JP5976638B2 (en) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of arginyl tRNA synthetase
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
EP2575856B1 (en) 2010-05-27 2017-08-16 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
JP5857056B2 (en) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー Use of cell penetrating peptide inhibitors of the JNK signaling pathway to treat chronic or non-chronic inflammatory eye diseases
CN103221054A (en) 2010-11-17 2013-07-24 日本化药株式会社 Novel polymer derivative of cytidine metabolism antagonist
WO2012066376A1 (en) * 2010-11-18 2012-05-24 Centre National De La Recherche Scientifique - Cnrs - Inhibitors of apoptosis and uses thereof
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
RU2623426C2 (en) 2011-09-11 2017-06-26 Ниппон Каяку Кабусики Кайся Method of obtaining a block copolymer
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US20150064141A1 (en) 2012-04-05 2015-03-05 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
WO2013162729A1 (en) 2012-04-24 2013-10-31 The Board Of Trustees Of The Leland Stanford Junior University Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
ES2728782T3 (en) 2012-05-25 2019-10-28 Univ California Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation
JP2015529073A (en) 2012-08-20 2015-10-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Polynucleotide having bioreversible group
MX370929B (en) 2012-10-28 2020-01-08 Revance Therapeutics Inc Compositions and methods for safe treatment of rhinitis.
US11491088B2 (en) 2012-11-06 2022-11-08 CoLabs International Corporation Compositions containing a capsule with a moisturizing agent
US11707421B2 (en) 2012-11-06 2023-07-25 Colabs Int'l Corp. Compositions containing a flexible derived capsule with an active agent
US11690793B2 (en) 2012-11-06 2023-07-04 Colabs Int'l Corp. Composition containing a cellulose derived capsule with a sunscreen
US10322301B2 (en) 2012-11-06 2019-06-18 CoLabs International Corporation Compositions containing a cellulose derived capsule with a sunscreen active agent
US11724134B2 (en) 2012-11-06 2023-08-15 CoLabs International Corporation Compositions containing a cellulose derived capsule with a sunscreen active agent
WO2014074555A1 (en) 2012-11-06 2014-05-15 CoLabs International Corporation Composition containing a cellulose derived capsule with a sunscreen
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
ES2822584T3 (en) 2013-05-03 2021-05-04 Univ California Induction of cyclic dinucleotides of type I interferon
JP2016523274A (en) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド Use of novel cell penetrating peptide inhibitors of the JNK signaling pathway to treat various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN106164255B (en) 2013-09-20 2020-02-14 隆萨有限公司 Method for nuclear reprogramming of cells
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
US9994831B2 (en) 2013-12-12 2018-06-12 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
RU2549908C1 (en) * 2014-03-12 2015-05-10 Общество С Ограниченной Ответственностью "Саентифик Фьючер Менеджмент" Biodegradable arginine-containing polymers
CA2949705A1 (en) 2014-05-21 2015-11-26 Cycloporters, Inc. Cell penetrating peptides and methods of making and using thereof
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US10898548B2 (en) 2015-01-29 2021-01-26 Leuvas Therapeutics Modulators of protein tyrosine phosphatase and uses thereof
US10377818B2 (en) 2015-01-30 2019-08-13 The Board Of Trustees Of The Leland Stanford Junior University Method of treating glioma
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
US20190048340A1 (en) 2015-09-24 2019-02-14 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
EA201891619A1 (en) 2016-01-11 2019-02-28 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити CHEMERAL PROTEINS AND METHODS OF REGULATING GENE EXPRESSION
CN108463229B (en) 2016-01-11 2023-10-17 斯坦福大学托管董事会 Chimeric proteins and immunotherapeutic methods
WO2017143071A1 (en) 2016-02-18 2017-08-24 The Regents Of The University Of California Methods and compositions for gene editing in stem cells
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
NZ755416A (en) 2016-12-19 2023-05-26 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111801417A (en) 2017-12-14 2020-10-20 克里斯珀医疗股份公司 Novel RNA-programmable endonuclease systems and their use in genome editing and other applications
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
US20210054353A1 (en) 2018-03-19 2021-02-25 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and uses thereof
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
KR102167755B1 (en) 2018-05-23 2020-10-19 주식회사 큐어바이오 Fragmented GRS polypeptide, mutants thereof and use thereof
WO2020006322A1 (en) 2018-06-27 2020-01-02 CoLabs International Corporation Compositions comprising silicon dioxide-based particles including one or more agents
CA3130789A1 (en) 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
WO2020186059A2 (en) 2019-03-12 2020-09-17 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN117157049A (en) 2021-01-24 2023-12-01 迈克尔·大卫·福雷斯特 ATP synthase inhibitor-cosmetic and therapeutic use
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
US20240141312A1 (en) 2021-06-11 2024-05-02 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
AU2022331568A1 (en) * 2021-08-19 2024-03-14 N1 Life, Inc. Taxol conjugate compounds, pharmaceutical compositions comprising the same, and methods for their use
AR126960A1 (en) 2021-09-01 2023-12-06 Dnovo Inc TRANSDIFFERENTIATION OF NON-HAIR FOLLICLE STEM CELLS TO NON-INDUCED HAIR FOLLICLE STEM CELLS
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
AR127419A1 (en) 2021-10-20 2024-01-24 Dnovo Inc TRANSDIFFERENTIATION OF NON-DERMIC PAPILLA CELLS TO DERMAL PAPILLA CELLS
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA31841A (en) 1889-07-26 Stephen Strange Mail bag rack and distributing table
CA31845A (en) 1889-08-01 George M. Dunham Nut machine
CA65237A (en) 1899-06-24 1899-12-06 Edwin Adlebert Leland Water purifying apparatus
DE2967069D1 (en) 1978-01-16 1984-08-02 Univ Boston Effecting cellular uptake of molecules
SE453510B (en) * 1980-12-29 1988-02-08 Toyo Jozo Kk PEPTIME FOR ANALYSIS OF HUMANT PARATYROID HORMON
CA2071214C (en) 1989-12-21 2006-06-06 Alan Frankel Method of delivering molecules into eukaryotic cells
US5866123A (en) * 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
DK36392D0 (en) * 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
US5985623A (en) * 1995-01-24 1999-11-16 Shin-Etsu Bio, Inc. DNA segments and methods for increasing polysaccharide production
ES2210761T3 (en) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITION AND PROCEDURE TO IMPROVE TRANSPORTATION THROUGH BIOLOGICAL MEMBERS.
US6548651B1 (en) * 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
WO2000074701A2 (en) 1999-06-05 2000-12-14 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US7070807B2 (en) * 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
WO2002065986A2 (en) * 2001-02-16 2002-08-29 Cellgate, Inc. Transporters comprising spaced arginine moieties

Also Published As

Publication number Publication date
CA2437983A1 (en) 2002-08-29
CA2437983C (en) 2011-10-25
WO2002065986A2 (en) 2002-08-29
AU2002306500C1 (en) 2006-09-28
US20120225826A1 (en) 2012-09-06
WO2002065986A9 (en) 2003-03-13
EP1401473A2 (en) 2004-03-31
US7585834B2 (en) 2009-09-08
DE60233137D1 (en) 2009-09-10
US20100081618A1 (en) 2010-04-01
EP1401473A4 (en) 2004-07-28
US20030032593A1 (en) 2003-02-13
AU2002306500B2 (en) 2006-04-06
WO2002065986A3 (en) 2004-01-22
ATE437647T1 (en) 2009-08-15
EP1401473B1 (en) 2009-07-29
JP2005508832A (en) 2005-04-07

Similar Documents

Publication Publication Date Title
MXPA03007358A (en) Transporters comprising spaced arginine moieties.
DE69818987D1 (en) COMPOSITION AND METHOD FOR DELAYING TRANSPORT BY BIOLOGICAL MEMBRANES
DE60023841D1 (en) PROCESS FOR PREPARING ALKYLATED SALICYLAMIDE
ATE260658T1 (en) PHARMACEUTICAL PREPARATIONS FOR REDUCING RESPIRATORY DEPRESSION
MA29614B1 (en) AGRICULTURAL COMPOSITION
DE60031999D1 (en) Stabilized Liquid Pharmaceutical Composition Containing Polypeptids
BR0115447A (en) Hepatitis C Tripeptide Inhibitors
MXPA02005536A (en) New aminopropylphosphinic acids.
IS2833B (en) ÉÅQ┴Bens├│├╛├¡├│sep├¡n┴og┴notkun┴├╛eirra┴gegn┴fitubl├Ó├░i┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴┴
AU2003301959A1 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
EA200400432A1 (en) UREA DERIVATIVES
BRPI0514420A (en) peptide, variant thereof, or a pharmaceutically acceptable salt thereof, composition, use of a peptide or peptide variant, substrate, and methods of treating or preventing a microbial infection, and treating a wound in an individual
RU2008126305A (en) NEW PEPTID
TR199701647A2 (en) �kame edilmi� purin t�revleri, bunlar�n imalat usul�
UA93529C2 (en) Salts of 9-oxoacridine-10-acetic acid with 1-alkylamno-1-desoxy-polyols
FR2846883B1 (en) COSMETIC COMPOSITION COMPRISING, AS ACTIVE INGREDIENT, AT LEAST ONE PEPTIDE AND USE OF THIS PEPTIDE
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
ATE404215T1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING HIV INFECTION
FI946128A (en) Biologically active compounds
HK1068344A1 (en) Dimeric compounds and their use as anti-viral agents
NO20025209D0 (en) Cyclipostins, their preparation and use
PL355852A1 (en) Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients
JPH1017487A (en) Preventing agent for delayed cataract
US20160130484A1 (en) Multi-component adhesive for producing an adhesive hydrogel
EP1348444A3 (en) Sustained release formulation of a peptide complexed with a polymer

Legal Events

Date Code Title Description
FG Grant or registration